Review examines the potential utility of GLP-1 receptor agonists in mast cell activation syndrome, where their anti-inflammatory properties may help manage this challenging condition.
Mast cells have GLP-1RGLP-1 receptors on mast cells suggest GLP-1 drugs could directly reduce mast cell activation and mediator release
What the researchers found
GLP-1 drugs may benefit mast cell activation syndrome through anti-inflammatory effects on mast cells and immune modulation, addressing an unmet need.
Why it matters
MCAS is underdiagnosed and undertreated. Finding that GLP-1 drugs — already taken by many MCAS patients for weight management — may also calm mast cell activation could improve care for this challenging condition.
The numbers in context
Mast cells can express hundreds of potent mediators. MCAS involves great heterogeneity in symptoms due to diverse gene mutation profiles.
How the study worked
Review of GLP-1 receptor expression on mast cells, GLP-1 drug anti-inflammatory mechanisms, and potential application in MCAS management.
Who was studied
Patients with mast cell activation syndrome
What this study cannot tell us
Limited direct evidence for GLP-1 drugs in MCAS. Most data on GLP-1 mast cell effects is preclinical. MCAS is heterogeneous and patients may respond differently.
How to read the evidence
Preliminary evidence: review proposing a novel application based on mechanistic rationale with limited direct clinical evidence.
When this study was published
Published in 2025. Proposes a novel application for GLP-1 drugs in immunology.
The bigger picture
GLP-1 drugs' expanding anti-inflammatory profile continues to reveal new potential applications. MCAS joins a growing list of inflammatory conditions where GLP-1 drugs may provide benefit beyond metabolic effects.
Questions still open
- Do MCAS patients on GLP-1 drugs report fewer mast cell activation episodes?
- Which GLP-1 drug would be most effective for MCAS?
- Could GLP-1 drugs be combined with traditional mast cell stabilizers for synergistic benefit?
Common questions
Can GLP-1 drugs help with mast cell disease?
What is mast cell activation syndrome?
Read the original research
Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.
The American journal of the medical sciences, 370(4), 377-382
Citation
Afrin, Lawrence B; Weinstock, Leonard B; Dempsey, Tania T; Aschenbrenner, Katja; Blitshteyn, Svetlana; Schofield, Jill R. (2025). Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.. The American journal of the medical sciences, 370(4), 377-382. https://doi.org/10.1016/j.amjms.2025.07.006